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Reply to Opportunity Cost of
Annual Screening Mammography
We thank Dr. Keen for responding to our article.1
Much of his response is regarding cost, which is beyond
the scope of our article and to our knowledge is not dis-
cussed in any of the national organization screening
guidelines. We agree that more screening results in
more direct financial expenditures for screening if the
number of screening mammograms is used as a surro-
gate for cost. We also agree that more aggressive screen-
ing regimens result in more life-years gained and more
breast cancer deaths averted. However, Dr. Keen’s cost
analysis is limited. Cost analysis of a screening program
is complex and should not be restricted to insurer direct
costs but rather should include the financial costs and
burdens of not screening or screening less aggressively
(ie, costs of alternative managements). These costs in-
clude lost productivity from increased morbidity and
mortality (a major opportunity cost), the incremental
costs of treating patients with later stage cancer, the cost
of treating more cases of metastatic breast cancer, and
the costs associated with symptomatic assessments of
unscreened women. The economic cost due to lost pro-
ductivity alone secondary to the (avoidable) death of a
single woman in her 40s is $1.4 million, which equates
to $1.4 billion per 1000 lives saved.2 Medical insurers
do not cover these large costs. The treatment of patients
with metastatic breast cancer is estimated as $250,000
per woman.3 Costs that are more difficult to estimate
are those related to excess morbidity such as treatment-
related cardiomyopathy, peripheral neuropathy, and
lymphedema.
Another focus of Dr. Keen’s letter is overdiagnosis.
We explicitly stated in the “Methods” section why our ar-
ticle did not discuss overdiagnosis: “Because both CIS-
NET [Cancer Intervention and Surveillance Modeling
Network] modelers and the USPSTF [US Preventive
Services Task Force] acknowledge that ‘methods for esti-
mating overdiagnosis at a population level are not well
established’ and ‘Existing science does not allow for the
ability to determine precisely what proportion of cancer
diagnosed by mammography today reflects overdiagnosis,
and estimates vary widely depending on the data source
and method of calculation used,’ the decision was made
not to include overdiagnosis in this study’s risk asses-
sment.”1 However, because Dr. Keen raises the issue, we
would like to stress that overdiagnosis is not reduced by
screening less frequently or by initiating screening at a lat-
er age. There now is strong evidence that all cases of
screen-detected invasive cancer and ductal carcinoma in
situ, if untreated, remain suspicious and are detected at
the time of the next screening, meaning that less intensive
screening may delay but does not reduce overdiagnosis.4
Therefore, overdiagnosis should not be used as a rationale
for delaying initiation of screening until after age 40 years
or for screening biennially instead of annually. Further-
more, Johns et al recently reported an overdiagnosis rate
of only 0.3% in a large screening study from the United
Kingdom after an appropriate follow-up period.5
Women considering screening mammography
should be aware that the greatest reduction in breast
cancer-specific mortality is achieved with annual screen-
ing mammography starting at age 40 years, with CIS-
NET computer models demonstrating a nearly 40%
reduction in breast cancer-specific mortality compared
with only a 23% reduction associated with biennial
screening of women aged 50 to 74 years.1 Screening
mammography decisions should be made by women,
not for women.
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Evaluation of Magnetic
Resonance Imaging and Targeted
Biopsy: The Difficulty of Finding
the Right Reference Standard
We read with interest the study by Truong et al,1 who
have proposed a novel tool for predicting benign prostate
pathology after a prior negative 12-core systematic biopsy.
The study included 285 patients, and 46.3% had benign
histological findings after targeted biopsy despite abnor-
mal magnetic resonance imaging (MRI). This was defined
as a false-positive MRI.
This approach highlights the most challenging and
controversial aspect of evaluating a targeted biopsy: defin-
ing the clear reference standard. Because targeted biopsy is
used in an interdisciplinary setting, all physicians involved
(eg, urologists, radiologists, and pathologists) have a par-
ticular learning curve and must contend with uncertainty
in the interpretation of their results.2 Gaziev et al3 eluci-
dated this in a recent study showing that radiologists and
urologists as well as technological differences could affect
targeted biopsy results. In other words, using targeted bi-
opsy results as the reference standard has clear limitations.
If prostate MRI reveals suspicious lesions and the subse-
quent targeted biopsy yields benign histologic findings,
there are theoretically 2 possible sources of error: the Pros-
tate Imaging Reporting and Data System score is falsely
high, or the targeted biopsy has failed to accurately sample
the lesion in question. To underscore this, Cash et al4 ana-
lyzed a subgroup of 61 patients with suspicious MRI find-
ings, a negative targeted biopsy, and an additional
random systematic biopsy, which still revealed a high rate
of clinically significant prostate cancer. In this study, both
the failure of the targeted approach to catch the suspicious
lesion and the inaccurately positive MRI scores contribut-
ed to these findings.
Despite these limitations, the objective that Truong
et al1 tried to investigate with their study is still useful:
persistent imaging and laboratory evidence for prostate
cancer despite a negative biopsy is a common and vexing
problem. The ideal setting for creating a predictive nomo-
gram to this end would involve MRI analysis and corre-
sponding biopsy results together with whole-mount
specimens of the prostate to truly evaluate the diagnostic
accuracy of the new technology. The drawback is that this
would sample only those patients who ultimately went on
to undergo radical prostatectomy, and thus a clear selec-
tion bias would be introduced. Thompson et al5 studied
this question with such a patient cohort, but they did not
seek to develop a nomogram. The goal of developing and
validating a standardized tool to help to reduce the num-
ber of unnecessary biopsies is clearly worthwhile, but we
must take into account the underlying limitations of how
these data were obtained.
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